86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

109 trials found

diseases per page:

Showing 1 to 10 of 109 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04039464 (ClinicalTrials.gov)	August 1, 2022	1/7/2019	Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension	Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension	Pediatric Pulmonary Hypertension	Drug: Mono-Therapy with Sildenafil;Drug: Duo-Therapy with Sildenafil + Bosentan	Johns Hopkins University	NULL	Recruiting	4 Months	18 Years	All	100	Phase 3	United States;Canada
2	NCT04991207 (ClinicalTrials.gov)	February 6, 2018	28/7/2021	Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan	An Open-label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 105 ...	Pulmonary Arterial Hypertension	Drug: BIA 5-1058;Drug: bosentan	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	44	Phase 1	Germany
3	NCT03053739 (ClinicalTrials.gov)	December 2016	29/12/2016	To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in ...	Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmon ...	Associated Pulmonary Arterial Hypertension	Drug: Sildenafil 20mg and Bosentan 62.5mg;Drug: Sildenafil 20mg and Placebo	Postgraduate Institute of Medical Education and Research	NULL	Recruiting	18 Years	N/A	All	50	Phase 4	India
4	NCT02885012 (ClinicalTrials.gov)	June 2016	3/5/2016	Crossover Study From Macitentan or Bosentan Over to Ambrisentan	A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan (Le ...	Pulmonary Arterial Hypertension	Drug: Ambrisentan	Medical University of South Carolina	Ochsner Health System	Terminated	18 Years	80 Years	All	3	Phase 4	United States
5	ChiCTR-OON-17013521	2015-02-01	2017-11-24	Transition from ambrisentan to bosentanin pulmonary arterial hypertension: A single center prospecti ...	Transition from ambrisentan to bosentanin pulmonary arterial hypertension: A single center prospecti ...	pulmonary arterial hypertension	ambrisentan group:oral ambrisentan;bosentan group:oral bosentan;	Shanghai Pulmonary Hospital	NULL	Completed			Male	ambrisentan group:12;bosentan group:8;		China
6	NCT01827059 (ClinicalTrials.gov)	October 2013	5/4/2013	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE	A Randomized Placebo Controlled Trial to Analyze Changes in Pulmonary Arterial Pressures at Peak Exe ...	Pulmonary Arterial Hypertension;Congenital Heart Disease	Drug: Bosentan;Drug: Placebo	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	NULL	Active, not recruiting	18 Years	N/A	All	12	Phase 2	Netherlands
7	JPRN-JapicCTI-132155	01/8/2013	11/06/2013	Bosentan extension study for PAH pediatric patients	Open-label, long-term, efficacy, safety, and tolerability extension study using the pediatric formul ...	Pulmonary arterial hypertension (PAH)	Intervention name : Ro 47-0203 / ACT-050088 INN of the intervention : bosentan Dosage And administrati ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	5	Phase 3	NULL
8	JPRN-JapicCTI-132154	01/5/2013		Bosentan for PAH pediatric patients	Open-label, multicenter study to assess the efficacy, safety, tolerability, and pharmacokinetics of ...	Pulmonary arterial hypertension (PAH)	Intervention name : Ro47-0203 / ACT-050088 INN of the intervention : bosentan Dosage And administratio ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	5	Phase 3	NULL
9	NCT03236818 (ClinicalTrials.gov)	May 2013	18/3/2013	Goal Oriented Strategy to Preserve Ejection Fraction Trial	Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Pres ...	Pulmonary Arterial Hypertension	Drug: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)	VU University Medical Center	NULL	Active, not recruiting	18 Years	80 Years	All	30	Phase 4	Netherlands
10	EUCTR2010-021825-11-BG (EUCTR)	02/01/2013	20/11/2012	A 7-month research project for children aged from 3 months to 11 years with pulmonary arterial hyper ...	An open label, prospective multicenter study to assess the pharmacokinetics, tolerability, safety an ...	Pulmonary arterial hypertension (PAH) in children MedDRA version: 14.1;Level: LLT;Classification cod ...	Trade Name: Tracleer Product Name: bosentan INN or Proposed INN: BOSENTAN MONOHYDRATE Other descriptive ...	Actelion Pharmaceuticals Ltd.	NULL	Not Recruiting			Female: yes Male: yes	64	Phase 3	Serbia;United States;Belarus;Spain;Ukraine;Israel;Russian Federation;Italy;India;France;Hungary;Czec ...

First Previous1 2 3 4 5…11Next Last